Regeneron Pharmaceuticals (REGN) 10-K2023 FY Annual report

Filed: 5 Feb 24, 9:16am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: African, AI, Almirall, amyloid, ancestry, antitumor, artificial, ASCO, atezolizumab, atrophy, autoimmune, avelumab, Bavencio, BCIL, Biocon, biometric, BioNTech, cardiomyopathy, Catalent, causation, Cencora, CHANGETM, Chinese, CISO, clause, Clawback, coalition, contravention, CVR, david, Davutamig, Decibel, deep, deposition, disaggregated, discourse, disqualifying, distributor, durvalumab, EGFR, eleven, ENDO, epidemic, Erosion, footprint, geopolitical, guarini, harbor, HD, House, insoluble, intelligence, interlocutory, iron, ISEF, Israel, kathryn, KGaA, lebrikizumab, lifelong, maximal, Meharry, mentoring, misuse, mRNA, Multidistrict, Munich, muscular, myostatin, neck, neurological, nivolumab, NL, noninfringement, Nordisk, Novo, obstructive, odesivimab, overload, overseen, overwhelming, pemphigoid, Pillar, pretrial, pulmonary, remeasured, repair, respiratory, restore, Retina, robust, rooted, schenkein, scrutinize, semaglutide, Seoul, Sonoma, SPC, stored, STS, Thoracic, Transfusion, transient, Treg, triple, uncontrolled, undergoing, Unified, unintended, unresolved, UPC, vast, vector, Veopoz, verification, vertical, wAMD, White, worsening, XI, Yesafili, yuan

Removed: abatacept, accelerate, Actemra, allocation, alternating, AMD, AmerisourceBergen, anniversary, applicant, appointed, Asian, bear, bridge, cat, checkmark, Chengdu, China, Conbercept, consortium, contamination, contrary, coronary, counsel, counterpart, creation, damaged, deducting, devote, direction, disposed, disrupt, disrupted, distancing, duty, dyslipidemia, earliest, Ebola, economy, eliminate, emerge, evolocumab, faced, filgotinib, flat, fluid, Genentech, Gilead, hand, harmful, Hong, hyperlipidemia, Immunex, impede, inclisiran, inducible, infarction, inpatient, introduction, invalidate, investigating, ITC, Jyseleca, Kanghong, knee, Kong, Lab, Leqvio, loan, Macau, magnitude, mainland, Marc, microbial, mild, mixed, myocardial, NASH, NDA, Neovascular, neutralize, NGF, NME, NV, occurred, ordered, Orencia, owed, peanut, permanently, PFS, pledge, port, postponement, predominately, progressing, prohibition, purported, recession, recombinant, recoup, redeem, refinance, rentable, repaid, Repatha, repay, residence, responding, rest, retained, revascularization, revise, revoke, rheumatoid, roy, Secretary, shelter, Solution, surfaced, sustain, Taiwan, Tariff, task, temporarily, tocilizumab, unsatisfied, vaccination, voucher, Wuhan, Zai

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated REGN transcripts

REGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 31.1

Certification of Principal Executive Officer Pursuant to

Rule 13a-14(a) under the Securities Exchange Act

of 1934, as Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Leonard S. Schleifer, certify that:

1.I have reviewed this annual report on Form 10-K of Regeneron Pharmaceuticals, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:	February 5, 2024	/s/ Leonard S. Schleifer
		Leonard S. Schleifer, M.D., Ph.D.
		President and Chief Executive Officer
		(Principal Executive Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.